California Institute for Regenerative Medicine

**Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis**

**Grant Award Details**

Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis

**Grant Type:** Clinical Trial Stage Projects

**Grant Number:** CLIN2-09284

**Project Objective:** Phase 1/2a clinical trial

**Investigator:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Clive Svendsen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institution</td>
<td>Cedars-Sinai Medical Center</td>
</tr>
<tr>
<td>Type</td>
<td>PI</td>
</tr>
</tbody>
</table>

**Disease Focus:** Amyotrophic Lateral Sclerosis, Neurological Disorders

**Human Stem Cell Use:** Adult Stem Cell

**Award Value:** $6,154,067

**Status:** Active

**Grant Application Details**

**Application Title:** Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis
Public Abstract: Therapeutic Candidate or Device
CNS10-NPC-GDNF - a neural progenitor cell secreting GDNF

Indication
ALS

Therapeutic Mechanism
This therapy will replace damaged astrocytes. The new astrocytes will release paracrine factors. As the cells have been modified to release GDNF they will also provide this factor to dying motor neurons.

Unmet Medical Need
There is no treatment or cure for ALS. Thus there is a huge unmet medical need.

Project Objective
Phase 1/2a clinical trial

Major Proposed Activities
Assess clinical safety of the therapeutic product

Statement of Benefit to California: ALS is a devastating disease and there are over 6,000 cases in CA. If this treatment works it will provide one of the only ways to slow down motor neuron disease progression. This illness costs the state of California millions of dollars in healthcare costs and immense suffering to those Californians affected by the disease.